Review





Similar Products

cyr61  (Novus Biologicals)
90
Novus Biologicals cyr61
<t>CYR61</t> expression correlates with breast cancer cell invasiveness. (A) Relative CYR61 expression of invasive breast cancer cell lines compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 6; MDA-MB-231 n = 4; HCC1806 n = 3; * P < 0.05 ; *** P < 0.005 (B) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 36; T47D-EMT n = 36; MDA-MB-231 n = 24; HCC1806 n = 54; ** P < 0.01; **** P < 0.0001 (C) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells transient transfected with CYR61 siRNA for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. MCF-7-EMT n = 36; T47D-EMT n = 18; MDA-MB-231 n = 18; HCC1806 n = 36; ** P < 0.01 ; **** P < 0.0001 (D) 3D invasion analysis of breast cancer spheroids seeded after transient siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 6; MDA-MB-231 n = 5; HCC1806 n = 6; ** P < 0.01 ; *** P < 0.005 (E) 3D invasion analysis of breast cancer spheroids treated with recombinant human CYR61 (rhCYR61). Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel+ rhCYR61). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7 n = 3; T47D n = 3; *** P < 0.005 (F) Proteolytic activity of non-invasive breast cancer cells treated with rhCYR61 was asses by measurement of fluorescence 24 h after seeding cells on wells coated with FITC-labeled gelatin. Relative proteolytic activity of rhCYR61 treated cells was compared to proteolytic activity of control cells. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7 n = 3; T47D n = 3 * P < 0.05.
Cyr61, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cyr61/product/Novus Biologicals
Average 90 stars, based on 1 article reviews
cyr61 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


CYR61 expression correlates with breast cancer cell invasiveness. (A) Relative CYR61 expression of invasive breast cancer cell lines compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 6; MDA-MB-231 n = 4; HCC1806 n = 3; * P < 0.05 ; *** P < 0.005 (B) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 36; T47D-EMT n = 36; MDA-MB-231 n = 24; HCC1806 n = 54; ** P < 0.01; **** P < 0.0001 (C) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells transient transfected with CYR61 siRNA for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. MCF-7-EMT n = 36; T47D-EMT n = 18; MDA-MB-231 n = 18; HCC1806 n = 36; ** P < 0.01 ; **** P < 0.0001 (D) 3D invasion analysis of breast cancer spheroids seeded after transient siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 6; MDA-MB-231 n = 5; HCC1806 n = 6; ** P < 0.01 ; *** P < 0.005 (E) 3D invasion analysis of breast cancer spheroids treated with recombinant human CYR61 (rhCYR61). Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel+ rhCYR61). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7 n = 3; T47D n = 3; *** P < 0.005 (F) Proteolytic activity of non-invasive breast cancer cells treated with rhCYR61 was asses by measurement of fluorescence 24 h after seeding cells on wells coated with FITC-labeled gelatin. Relative proteolytic activity of rhCYR61 treated cells was compared to proteolytic activity of control cells. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7 n = 3; T47D n = 3 * P < 0.05.

Journal: Frontiers in Oncology

Article Title: Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

doi: 10.3389/fonc.2019.01074

Figure Lengend Snippet: CYR61 expression correlates with breast cancer cell invasiveness. (A) Relative CYR61 expression of invasive breast cancer cell lines compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 6; MDA-MB-231 n = 4; HCC1806 n = 3; * P < 0.05 ; *** P < 0.005 (B) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 36; T47D-EMT n = 36; MDA-MB-231 n = 24; HCC1806 n = 54; ** P < 0.01; **** P < 0.0001 (C) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells transient transfected with CYR61 siRNA for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. MCF-7-EMT n = 36; T47D-EMT n = 18; MDA-MB-231 n = 18; HCC1806 n = 36; ** P < 0.01 ; **** P < 0.0001 (D) 3D invasion analysis of breast cancer spheroids seeded after transient siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 6; MDA-MB-231 n = 5; HCC1806 n = 6; ** P < 0.01 ; *** P < 0.005 (E) 3D invasion analysis of breast cancer spheroids treated with recombinant human CYR61 (rhCYR61). Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel+ rhCYR61). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7 n = 3; T47D n = 3; *** P < 0.005 (F) Proteolytic activity of non-invasive breast cancer cells treated with rhCYR61 was asses by measurement of fluorescence 24 h after seeding cells on wells coated with FITC-labeled gelatin. Relative proteolytic activity of rhCYR61 treated cells was compared to proteolytic activity of control cells. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7 n = 3; T47D n = 3 * P < 0.05.

Article Snippet: Sample sections were incubated over night with primary labeled antibodies against S100A4 (NBP2-54580AF488; Alexa Fluor 488 labeled; 5 μg/ml; Novus Biologicals, Centennial, CO, USA) and CYR61 (NB100-356R; DyLight labeled; 5 μg/ml; Novus Biologicals) at 4°C.

Techniques: Expressing, Two Tailed Test, Cell Culture, Transfection, Selection, Control, Recombinant, Activity Assay, Fluorescence, Labeling

Suppression of CYR61 reduces S100A4 expression. (A) Scheme illustrating hypothesis of CYR61-dependent cell invasion regulation. (B) Relative S100A4 expression of invasive breast cancer cell lines compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 5; MDA-MB-231 n = 4; HCC1806 n = 6; * P < 0.05 ; *** P < 0.005 (C) Relative S100A4 expression of invasive breast cancer cell lines 96 h after transient CYR61 transfection compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 4; T47D-EMT n = 3; MDA-MB-231 n = 4; HCC1806 n = 3; * P < 0.05; ** P < 0.01; *** P < 0.005 (D) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells transient transfected with S100A4 siRNA for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. MCF-7-EMT n = 36; T47D-EMT n = 36; MDA-MB-231 n = 24; HCC1806 n = 36; * P < 0.05; *** P < 0.005; **** P < 0.0001 (E) 3D invasion analysis of breast cancer spheroids seeded after transient siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 6; T47D-EMT n = 6; MDA-MB-231 n = 12; HCC1806 n = 6; *** P < 0.005; **** P < 0.0001 (F) 3D invasion analysis of breast cancer spheroids seeded after transient S100A4 siRNA transfection and treated with rhCYR61. Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel + rhCYR61). Area growth was compared to area growth of S100A4- spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 4; T47D-EMT n = 4; MDA-MB-231 n = 5; HCC1806 n = 6; * P < 0.05 ; ** P < 0.001.

Journal: Frontiers in Oncology

Article Title: Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

doi: 10.3389/fonc.2019.01074

Figure Lengend Snippet: Suppression of CYR61 reduces S100A4 expression. (A) Scheme illustrating hypothesis of CYR61-dependent cell invasion regulation. (B) Relative S100A4 expression of invasive breast cancer cell lines compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 5; T47D-EMT n = 5; MDA-MB-231 n = 4; HCC1806 n = 6; * P < 0.05 ; *** P < 0.005 (C) Relative S100A4 expression of invasive breast cancer cell lines 96 h after transient CYR61 transfection compared to non-invasive controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 4; T47D-EMT n = 3; MDA-MB-231 n = 4; HCC1806 n = 3; * P < 0.05; ** P < 0.01; *** P < 0.005 (D) 2D Invasion analysis of co-cultured (MG-63, osteosarcoma cells) breast cancer cells transient transfected with S100A4 siRNA for 96 h. Percentage of cell invasion compared to controls was assessed by counting invaded cells under the filter in 4 random filter regions. Data represent mean ± SEM. MCF-7-EMT n = 36; T47D-EMT n = 36; MDA-MB-231 n = 24; HCC1806 n = 36; * P < 0.05; *** P < 0.005; **** P < 0.0001 (E) 3D invasion analysis of breast cancer spheroids seeded after transient siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 6; T47D-EMT n = 6; MDA-MB-231 n = 12; HCC1806 n = 6; *** P < 0.005; **** P < 0.0001 (F) 3D invasion analysis of breast cancer spheroids seeded after transient S100A4 siRNA transfection and treated with rhCYR61. Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel + rhCYR61). Area growth was compared to area growth of S100A4- spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 4; T47D-EMT n = 4; MDA-MB-231 n = 5; HCC1806 n = 6; * P < 0.05 ; ** P < 0.001.

Article Snippet: Sample sections were incubated over night with primary labeled antibodies against S100A4 (NBP2-54580AF488; Alexa Fluor 488 labeled; 5 μg/ml; Novus Biologicals, Centennial, CO, USA) and CYR61 (NB100-356R; DyLight labeled; 5 μg/ml; Novus Biologicals) at 4°C.

Techniques: Expressing, Two Tailed Test, Transfection, Cell Culture, Selection, Control

ERK1/2 activity is transducer of CYR61 mediated S100A4 regulation. (A) Scheme illustrating hypothesis of CYR61 regulating S100A4 in a p-ERK1/2 dependent manner. (B) ERK1/2 and p-Erk1/2 (Thr202/Tyr204) expression in different breast cancer cell lines detected by western blotting. (C) ERK1/2 and p-Erk1/2 (Thr202/Tyr204) and CYR61 expression in different breast cancer cell lines after transient CYR61 transfection detected by western blotting. (D) Relative S100A4 expression of invasive breast cancer cell lines treated with 10 μM U0126 compared to DMSO controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. n = 3; * P < 0.05 ; ** P < 0.01 ; *** P < 0.005 (E) 3D invasion analysis of breast cancer spheroids seeded after U0126 treatment. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel + 10 μM U0126). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 6; T47D-EMT n = 5; MDA-MB-231 n = 6; HCC1806 n = 5; ** P < 0.01 ; *** P < 0.005 ; **** P < 0.0001 (F) Analysis of relative AlamarBlue reduction as indicator for cell viability. Breast cancer cell spheroids were grown and AlamarBlue reduction was assessed 48 h after adding Matrigel and 10 μM U0126 at 4 h incubation. Relative AlamarBlue reduction was calculated compared to DMSO control spheroids. Data represent mean ± SEM. MCF-7-EMT n = 3; T47D-EMT n = 4; MDA-MB-231 n = 3; HCC1806 n = 3; * P < 0.05 ; ** P < 0.01.

Journal: Frontiers in Oncology

Article Title: Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

doi: 10.3389/fonc.2019.01074

Figure Lengend Snippet: ERK1/2 activity is transducer of CYR61 mediated S100A4 regulation. (A) Scheme illustrating hypothesis of CYR61 regulating S100A4 in a p-ERK1/2 dependent manner. (B) ERK1/2 and p-Erk1/2 (Thr202/Tyr204) expression in different breast cancer cell lines detected by western blotting. (C) ERK1/2 and p-Erk1/2 (Thr202/Tyr204) and CYR61 expression in different breast cancer cell lines after transient CYR61 transfection detected by western blotting. (D) Relative S100A4 expression of invasive breast cancer cell lines treated with 10 μM U0126 compared to DMSO controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. n = 3; * P < 0.05 ; ** P < 0.01 ; *** P < 0.005 (E) 3D invasion analysis of breast cancer spheroids seeded after U0126 treatment. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel + 10 μM U0126). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 6; T47D-EMT n = 5; MDA-MB-231 n = 6; HCC1806 n = 5; ** P < 0.01 ; *** P < 0.005 ; **** P < 0.0001 (F) Analysis of relative AlamarBlue reduction as indicator for cell viability. Breast cancer cell spheroids were grown and AlamarBlue reduction was assessed 48 h after adding Matrigel and 10 μM U0126 at 4 h incubation. Relative AlamarBlue reduction was calculated compared to DMSO control spheroids. Data represent mean ± SEM. MCF-7-EMT n = 3; T47D-EMT n = 4; MDA-MB-231 n = 3; HCC1806 n = 3; * P < 0.05 ; ** P < 0.01.

Article Snippet: Sample sections were incubated over night with primary labeled antibodies against S100A4 (NBP2-54580AF488; Alexa Fluor 488 labeled; 5 μg/ml; Novus Biologicals, Centennial, CO, USA) and CYR61 (NB100-356R; DyLight labeled; 5 μg/ml; Novus Biologicals) at 4°C.

Techniques: Activity Assay, Expressing, Western Blot, Transfection, Two Tailed Test, Selection, Control, Incubation

Suppression of YAP reduces invasiveness through blocking CYR61-S100A4-pERK1/2 signaling. (A) Scheme illustrating hypothesis of YAP regulating S100A4 in a CYR61 - p-ERK1/2 dependent manner. (B) 3D invasion analysis of breast cancer spheroids seeded after transient YAP siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 4; T47D-EMT n = 5; MDA-MB-231 n = 12; HCC1806 n = 8; * P < 0.05 ; ** P < 0.01 ; *** P < 0.005 (C) Relative CYR61 expression of invasive breast cancer cell lines 48 h after transient YAP siRNA compared to controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. n = 3; * P < 0.05 ; ** P < 0.01 ; *** P < 0.005 (D) Relative S100A4 expression of invasive breast cancer cell lines 48 h after transient YAP siRNA compared to controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. n = 3; * P < 0.05 ; ** P < 0.01; (E) ERK1/2, p-Erk1/2 (Thr202/Tyr204) and YAP expression in different breast cancer cell lines after transient YAP siRNA transfection detected by western blotting. (F) 3D invasion analysis of breast cancer spheroids seeded after transient YAP siRNA transfection and treated with rhCYR61. Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel + rhCYR61). Area growth was compared to area growth of YAP- spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 6; T47D-EMT n = 6; MDA-MB-231 n = 4; HCC1806 n = 6.

Journal: Frontiers in Oncology

Article Title: Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

doi: 10.3389/fonc.2019.01074

Figure Lengend Snippet: Suppression of YAP reduces invasiveness through blocking CYR61-S100A4-pERK1/2 signaling. (A) Scheme illustrating hypothesis of YAP regulating S100A4 in a CYR61 - p-ERK1/2 dependent manner. (B) 3D invasion analysis of breast cancer spheroids seeded after transient YAP siRNA transfection. Spheroid area was assessed 48 h after adding Matrigel using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel). Area growth was compared to area growth of control spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 4; T47D-EMT n = 5; MDA-MB-231 n = 12; HCC1806 n = 8; * P < 0.05 ; ** P < 0.01 ; *** P < 0.005 (C) Relative CYR61 expression of invasive breast cancer cell lines 48 h after transient YAP siRNA compared to controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. n = 3; * P < 0.05 ; ** P < 0.01 ; *** P < 0.005 (D) Relative S100A4 expression of invasive breast cancer cell lines 48 h after transient YAP siRNA compared to controls. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. n = 3; * P < 0.05 ; ** P < 0.01; (E) ERK1/2, p-Erk1/2 (Thr202/Tyr204) and YAP expression in different breast cancer cell lines after transient YAP siRNA transfection detected by western blotting. (F) 3D invasion analysis of breast cancer spheroids seeded after transient YAP siRNA transfection and treated with rhCYR61. Spheroid area was assessed 48 h after adding Matrigel and rhCYR61 using polygonal selection and compared to spheroid area at time point 0 (adding of Matrigel + rhCYR61). Area growth was compared to area growth of YAP- spheroids. Data represent mean ± SEM. Using unpaired, two-tailed t -test analysis. MCF-7-EMT n = 6; T47D-EMT n = 6; MDA-MB-231 n = 4; HCC1806 n = 6.

Article Snippet: Sample sections were incubated over night with primary labeled antibodies against S100A4 (NBP2-54580AF488; Alexa Fluor 488 labeled; 5 μg/ml; Novus Biologicals, Centennial, CO, USA) and CYR61 (NB100-356R; DyLight labeled; 5 μg/ml; Novus Biologicals) at 4°C.

Techniques: Blocking Assay, Transfection, Selection, Control, Two Tailed Test, Expressing, Western Blot

CYR61 and S100A4 as prognostic marker for breast cancer progression. (A) Probability of distant metastasis free survival (DMFS) in 382 breast cancer patients with lymph node positive status according to CYR61expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 213226_at with a false-discovery rate (FDR) of 1%. Black line illustrates high CYR61 expression group and red line illustrates low CYR61 expression group. (B) Probability of DMFS in 382 breast cancer patients with lymph node positive status according to S100A4 expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 203186_at with a false-discovery rate (FDR) over 50%. Black line illustrates high S100A4 expression group and red line illustrates low S100A4 expression group. (C) Probability of remission free survival (RFS) in 1133 breast cancer patients with lymph node positive status according to CYR61 expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 213226_at with a false-discovery rate (FDR) of 1%. Black line illustrates high CYR61 expression group and red line illustrates low CYR61 expression group. (D) Probability of RFS in 1133 breast cancer patients with lymph node positive status according to CYR61 expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 203186_at with a false-discovery rate (FDR) over 50 %. Black line illustrates high S100A4 expression group and red line illustrates low S100A4 expression group. HR, hazard ratio.

Journal: Frontiers in Oncology

Article Title: Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

doi: 10.3389/fonc.2019.01074

Figure Lengend Snippet: CYR61 and S100A4 as prognostic marker for breast cancer progression. (A) Probability of distant metastasis free survival (DMFS) in 382 breast cancer patients with lymph node positive status according to CYR61expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 213226_at with a false-discovery rate (FDR) of 1%. Black line illustrates high CYR61 expression group and red line illustrates low CYR61 expression group. (B) Probability of DMFS in 382 breast cancer patients with lymph node positive status according to S100A4 expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 203186_at with a false-discovery rate (FDR) over 50%. Black line illustrates high S100A4 expression group and red line illustrates low S100A4 expression group. (C) Probability of remission free survival (RFS) in 1133 breast cancer patients with lymph node positive status according to CYR61 expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 213226_at with a false-discovery rate (FDR) of 1%. Black line illustrates high CYR61 expression group and red line illustrates low CYR61 expression group. (D) Probability of RFS in 1133 breast cancer patients with lymph node positive status according to CYR61 expression level. Kaplan–Meier plots were generated using Kaplan–Meier plotter ( www.kmplot.com ) data set 203186_at with a false-discovery rate (FDR) over 50 %. Black line illustrates high S100A4 expression group and red line illustrates low S100A4 expression group. HR, hazard ratio.

Article Snippet: Sample sections were incubated over night with primary labeled antibodies against S100A4 (NBP2-54580AF488; Alexa Fluor 488 labeled; 5 μg/ml; Novus Biologicals, Centennial, CO, USA) and CYR61 (NB100-356R; DyLight labeled; 5 μg/ml; Novus Biologicals) at 4°C.

Techniques: Marker, Generated, Expressing

CYR61 and S100A4 as therapeutic target for invasive and metastatic breast cancer. Immunofluorescence staining of three tissue arrays (biomax) containing 104 invasive ductal carcinoma tissue sections with corresponding metastatic carcinomas, further 21 invasive ductal carcinoma tissue sections and 8 normal breast tissue sections. With 33 of the carcinoma tissue sections being negative for the estrogen receptor and progesterone receptor and do not overexpress the Her2neu receptor (triple negative breast cancer, TNBC). (A) CYR61 and/or S100A4 expression analysis in 123 invasive ductal carcinoma tissue sections and corresponding lymph node sections from 104 patients (B) and representative immunofluorescence staining analyzed with a 100x oil objective (Axio ZEISS). (C) Within the 123 invasive ductal carcinomas patient tissue sections 33 were stated as being TNBC. (D) Normal breast tissue sections ( n = 8) were analyzed for their CYR61 and/ or S100A4 expression using immunofluorescence staining. Scale bar gauges 20 μm.

Journal: Frontiers in Oncology

Article Title: Inhibition of CYR61-S100A4 Axis Limits Breast Cancer Invasion

doi: 10.3389/fonc.2019.01074

Figure Lengend Snippet: CYR61 and S100A4 as therapeutic target for invasive and metastatic breast cancer. Immunofluorescence staining of three tissue arrays (biomax) containing 104 invasive ductal carcinoma tissue sections with corresponding metastatic carcinomas, further 21 invasive ductal carcinoma tissue sections and 8 normal breast tissue sections. With 33 of the carcinoma tissue sections being negative for the estrogen receptor and progesterone receptor and do not overexpress the Her2neu receptor (triple negative breast cancer, TNBC). (A) CYR61 and/or S100A4 expression analysis in 123 invasive ductal carcinoma tissue sections and corresponding lymph node sections from 104 patients (B) and representative immunofluorescence staining analyzed with a 100x oil objective (Axio ZEISS). (C) Within the 123 invasive ductal carcinomas patient tissue sections 33 were stated as being TNBC. (D) Normal breast tissue sections ( n = 8) were analyzed for their CYR61 and/ or S100A4 expression using immunofluorescence staining. Scale bar gauges 20 μm.

Article Snippet: Sample sections were incubated over night with primary labeled antibodies against S100A4 (NBP2-54580AF488; Alexa Fluor 488 labeled; 5 μg/ml; Novus Biologicals, Centennial, CO, USA) and CYR61 (NB100-356R; DyLight labeled; 5 μg/ml; Novus Biologicals) at 4°C.

Techniques: Immunofluorescence, Staining, Expressing